{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:16:34Z","timestamp":1789676194758,"version":"4.0.1"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Valproic acid (VPA) is an effective antiepileptic drug and mood stabilizer. A key characteristic of VPA is its high and saturable protein binding at higher concentrations. Although the unbound concentration of VPA is responsible for its pharmacological activity, total drug concentrations are monitored in routine clinical practice. Therapeutic drug monitoring (TDM) of unbound VPA is recommended for specific clinical situations. The goal of this study was to evaluate TDM requests for unbound VPA in clinical practice.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>All TDM requests at our laboratory for unbound VPA in 2014 and 2015 were evaluated retrospectively. In patients with potentially toxic unbound VPA concentrations (ie, &gt;12 mg\/L), we evaluated whether toxicity was noted and whether the dose adjustment advice was followed. Total and unbound VPA concentrations were measured by means of a validated immunoassay.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 273 unbound VPA serum concentrations in 132 different patients were analyzed. The main reasons for unbound VPA TDM were decreased renal function (34%) and a low serum albumin (27%). The median (range) unbound VPA concentration was 9.8 (2.5\u201347.6) mg\/L. In 49 patients (37%), the initial unbound VPA concentration was above the threshold of 12 mg\/L, potentially resulting in toxicity. Only 6 of these 49 patients had elevated total VPA concentrations. Clinical toxicity was noted in 38 of the 49 patients (77.6%) with elevated unbound VPA concentrations. Toxicities included drowsiness (n = 26), decreased consciousness (n = 4), rigidity (n = 2), and confusion (n = 2). In 36 of the 38 patients with elevated unbound VPA concentrations and clinical toxicity, a dose reduction was applied. In 27 of 36 patients who had their dose reduced, dose reduction was associated with improvement or resolution of VPA toxicity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>TDM of unbound VPA is an important tool to manage VPA therapy in selected, vulnerable patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000405","type":"journal-article","created":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T06:57:24Z","timestamp":1492757844000},"page":"269-272","source":"Crossref","is-referenced-by-count":26,"title":["Monitoring Protein-Unbound Valproic Acid Serum Concentrations in Clinical Practice"],"prefix":"10.1097","volume":"39","author":[{"given":"Eveline","family":"Wallenburg","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Rijnstate Hospital, Arnhem;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"Klok","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Rijnstate Hospital, Arnhem;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"de Jong","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Rijnstate Hospital, Arnhem;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"de Maat","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Rijnstate Hospital, Arnhem;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nielka","family":"van Erp","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Radboudumc, Nijmegen;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Stalpers-Konijnenburg","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Rijnstate Hospital, Arnhem; and"},{"name":"Stichting Pro Persona, Arnhem, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guus","family":"Essink","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Rijnstate Hospital, Arnhem;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthijs","family":"van Luin","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Rijnstate Hospital, Arnhem;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20230928","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1124\/pr.111.005512","article-title":"Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder","volume":"65","author":"Chiu","year":"2013","journal-title":"Pharmacol Rev."},{"issue":"suppl 2","key":"R3-20230928","first-page":"S2","article-title":"Antiepileptic drug mechanisms of action","volume":"36","author":"Macdonald","year":"1995","journal-title":"Epilepsia"},{"key":"R4-20230928","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00003088-198815060-00002","article-title":"Clinical pharmacokinetics of valproic acid\u20141988","volume":"15","author":"Zaccara","year":"1988","journal-title":"Clin Pharmacokinet."},{"key":"R5-20230928","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/FTD.0b013e3181c13a30","article-title":"Does valproic acid warrant therapeutic drug monitoring in bipolar affective disorder?","volume":"32","author":"Haymond","year":"2010","journal-title":"Ther Drug Monit."},{"key":"R6-20230928","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs\u2014best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"R7-20230928","first-page":"CD002216","article-title":"Therapeutic monitoring of antiepileptic drugs for epilepsy","author":"Tomson","year":"2007","journal-title":"Cochrane Database Syst Rev."},{"key":"R8-20230928","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/01.WNF.0000228209.69524.E8","article-title":"Therapeutic monitoring of valproate in psychiatry: how far have we progressed?","volume":"29","author":"Fleming","year":"2006","journal-title":"Clin Neuropharmacol."},{"key":"R10-20230928","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cca.2006.08.026","article-title":"Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management","volume":"377","author":"Dasgupta","year":"2007","journal-title":"Clin Chim Acta."},{"key":"R11-20230928","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/clinchem\/44.5.1085","article-title":"Standards of laboratory practice: antiepileptic drug monitoring. National Academy of Clinical Biochemistry","volume":"44","author":"Warner","year":"1998","journal-title":"Clin Chem."},{"key":"R12-20230928","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/00002512-200320020-00005","article-title":"Drug treatment of epilepsy in elderly people: focus on valproic Acid","volume":"20","author":"Stephen","year":"2003","journal-title":"Drugs Aging."},{"key":"R13-20230928","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1345\/aph.1P308","article-title":"High unbound fraction of valproic acid in a hypoalbuminemic critically ill patient on renal replacement therapy","volume":"45","author":"de Maat","year":"2011","journal-title":"Ann Pharmacother."},{"key":"R14-20230928","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1345\/aph.19147","article-title":"Elevated free fractions of valproic acid in a heart transplant patient with hypoalbuminemia","volume":"34","author":"Haroldson","year":"2000","journal-title":"Ann Pharmacother."},{"key":"R15-20230928","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2146\/ajhp140191","article-title":"Comparison of free fraction serum valproic acid concentrations between inpatients and outpatients","volume":"72","author":"Gibbs","year":"2015","journal-title":"Am J Health Syst Pharm."},{"key":"R16-20230928","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1586\/14737175.8.6.929","article-title":"Value of therapeutic drug monitoring in epilepsy","volume":"8","author":"Johannessen","year":"2008","journal-title":"Expert Rev Neurother."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201706000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T01:04:34Z","timestamp":1695863074000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201706000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000405","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}